UK markets closed

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
1.0800+0.0200 (+1.89%)
At close: 04:00PM EDT
1.0500 -0.03 (-2.78%)
After hours: 05:42PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-23,656
-21,486
-26,273
-43,019
-20,649
Depreciation & amortisation
696
692
727
873
2,039
Deferred income taxes
0
-1,803
0
0
-1,239
Stock-based compensation
4,772
4,640
4,287
3,519
2,227
Change in working capital
-5,397
-10,804
18,704
21,096
1,373
Accounts receivable
127
-446
50,314
-857
287
Accounts payable
-
-
-
21,645
308
Other working capital
-23,631
-29,240
646
-23,901
-19,817
Other non-cash items
-272
-588
-536
216
-81
Net cash provided by operating activities
-23,107
-28,566
1,059
-23,561
-19,753
Cash flows from investing activities
Investments in property, plant and equipment
-524
-674
-413
-340
-64
Purchases of investments
-8,685
-16,403
-53,412
0
-
Sales/maturities of investments
40,194
63,526
7,666
0
-
Other investing activities
-
-
-
14
41
Net cash used for investing activities
30,985
46,449
-46,159
9,745
13,038
Cash flows from financing activities
Debt repayment
-54
-54
-32
-20
-26
Common stock issued
20,662
6,625
148
30,865
5,127
Common stock repurchased
-23
-37
-17
-54
-27
Other financing activities
-
-199
-106
-1,101
-356
Net cash used provided by (used for) financing activities
20,443
6,423
1,632
36,930
29,865
Net change in cash
28,101
24,056
-44,341
23,094
23,087
Cash at beginning of period
16,021
11,936
56,277
33,183
10,096
Cash at end of period
44,342
35,992
11,936
56,277
33,183
Free cash flow
Operating cash flow
-23,107
-28,566
1,059
-23,561
-19,753
Capital expenditure
-524
-674
-413
-340
-64
Free cash flow
-23,631
-29,240
646
-23,901
-19,817